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Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder
among fertile women. Studies show reduced quality of life, anxiety, depression, body dis-
satisfaction, eating disorder, and sexual dysfunction, but the etiology of these disturbs
remains still debated. The aim of our study is to verify whether this hyperandrogenic
syndrome characterizes a strong psycho(patho)logical personality.
Method: Sixty PCOS subjects (mean age 25.8±4.7 years) were evaluated by anthropo-
metric, metabolic, hormonal, clinical, and psychological parameters. After the certainty of
the diagnosis of PCOS, the Rorschach test, according to Exner’s comprehensive system
(CS) and the Millon Clinical Multiaxial Inventory-III (MCMI-III) were administered to each
patient. The control group, on which the comparison was carried out, was composed by
40 healthy and aged compared women who were exclusively administered the Rorschach
test according to CS.
Results: MCMI-III evidenced axis II DSM-IV personality disorders [4.1% schizoid, depres-
sive, sadistic, negativistic (passive–aggressive), and masochistic, 6.1% avoiding, 12.2%
dependent, 20.4% histrionic, 16.3% narcissistic, 2.0% obsessive–compulsive], and axis I
DSM-IV psychiatric disorders: 10.2% anxiety, 2.0% somatoform disorder and bipolar dis-
order, 16.3% major depressive disorder. Finally, we found 44.9% delusional disorder and
4.1% thought disorder. Rorschach test’s results show 53.1% reduced coping abilities and
social skills, 55.1% depression, 30.6% perceptual distortion and cognitive slippage, 24.5%
constantly alert and worry, 8.1% at risk for suicide, and finally about 50% of our patients
had chronic stress.
Conclusion: PCOS women have relevant personality and psychiatric disorders, when
compared with normal subjects.
Keywords: polycystic ovary syndrome, personality, Rorschach, MCMI-III, psychopathology, personality disorder,
psychiatric disorder
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a heterogeneous gyneco-
logical endocrine disorder, characterized by chronic anovulation,
hyperandrogenism, and hyperinsulinism with insulin resistance,
which affects about 6–10% of women in reproductive age (1–3)
and profoundly affects the quality of life of these subjects (4, 5). In
fact, this hyperandrogenic syndrome is frequently characterized by
hirsutism, acne, alopecia, obesity, and irregular periods with infer-
tility and it is often treated as cosmetic problem. The existence of
a linkage between these latter clinical features and reduced qual-
ity of life was frequently suggested in several researches (6–8).
Other studies evidenced how physical symptoms caused mental
disorders, but depression and anxiety seem to be independent of
obesity and infertility, the most frequent symptoms of PCOS (9,
10). Also, the relationship between androgen excess and mood
remains still controversial because clinical and biochemical para-
meters of hyperandrogenism seem not directly cause of depression
(11). Again, diagnosis of PCOS was related to negative feelings,
such as frustration (67%), anxiety (16%), and sadness (10%),
although the (self-reported) level of knowledge about the ill-
ness was high and the women were aware that PCOS can be
treated and is not a deadly disease (12). Other authors reported
reduced scores in the sub-categories of perception about health in
general, physical performances, general behavior, and limitations
in family activities due to the “girls’ disease” (12). At the same
time, higher scores were reported in the rating of health condi-
tions, during the diagnostic pathway and above all the treatment
period, further supporting a dependent effect between clinical fea-
tures and psychological aspects. In different manner, several data
obtained in PCOS subjects reported that differences for the QoL
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are more related to the subjective perception of the illness’s seri-
ousness rather than to the clinical seriousness of the illness itself.
These data, therefore, suggest that a subjective feeling of discom-
fort might be totally unrelated to the clinical picture, although
objectively recorded. Again, other psychological aspects, such as
depression (8, 13), and/or anxiety (14, 15), have been empha-
sized in PCOS, but only few articles analyzed women’s personality
structure (16). In women with PCOS, Sahingoz et al. (17) assessed
a high prevalence of psychiatric and personality disorders, about
29.0 and 14.0%, respectively. They also reported 9.6% of mood
and 26.0% of anxiety disorders, 13.7% of social phobia, 11.0% of
generalized anxiety, and 12.3% of avoidant personality disorders,
according to DSM-IV axis I and II Diagnostic Criteria, respectively.
Again, Patients with borderline personality disorders, diagnosed
by SCID for DSM-IV, about 30.0% was affected by PCOS (18).
Personality disorders seem to be characterized by the tendency to
exhibit a tenuous stability, or lack of resilience, under conditions of
stress, by the inflexibility to adapt and by vicious cycles that repeats
once again their pathology. Again, the interaction of psychosocial
stressors and personality characteristics leads to the expression of
psychological symptoms, that is, axis II and axis IV interact to
produce axis I. Since no studies used Rorschach test or Millon
Clinical Multiaxial Inventory to analyze the personality structure
of subjects with PCOS, we believe it is useful to carefully study
and develop the personality aspects related to this hyperandro-
genic syndrome, as well as the psychopathological ones. Moreover,
to minimize the influence of diagnostic and therapeutic pathways,
we only studied young women, with comparable social and school
conditions, undergoing for the first time to the endocrine evalua-
tion for clinical features of hyperandrogenism and/or disorders of
menstrual cycle.
This study was performed in collaboration with the Division
of Endocrinology, Department of Internal Medicine of St. Orsola-
Malpighi Hospital, University of Bologna, and with the Clinical
Medical 3 of Health Centre/Hospital-University of Padua, on the
white patients coming from the northern provinces of Italy.
PATIENTS AND METHODS
SUBJECTS RECRUITMENT
Sixty Caucasian women, all of Italian origin, affected by certain
diagnosis of PCOS, were enrolled to participate in this research
study: 30 subjects from the Endocrinology Unit of St. Orsola-
Malpighi Hospital – University of Bologna and 30 subjects from
the Clinical Medical 3 of Health Centre/Hospital-University of
Padua. For all patients, it was the first time they turned to a Public
Health Institution to resolve their hyperandrogenic symptoms.
All women were hyperandrogenic (clinical presence of hir-
sutism with Ferriman–Gallwey score >8, acne or alopecia and/or
elevated androgen levels: testosterone (T )> 2.1 nmol/L and or
androstenedione (A)> 10.4 nmol/L or Free Androgen Index> 5
[FAI=Testosterone(nmol/L)/SHBG(nmol/L)× 100] and met the
diagnosis of PCOS, according to the Rotterdam criteria (19). Ovar-
ian ultrasound findings were performed by transvaginal or tran-
srectal pelvic ultrasound (US ESAOTE F.U.5, Probe of 6.5 MHz,
Milan, Italy) and PCO diagnosis were considered according to pre-
vious criteria (20). All subjects were no-smokers, no dieting, had
a normal glucose tolerance test and performed normal physical
activities, none drank alcoholic beverages or took any continuous
medications. According to PCOS diagnostic criteria, none had thy-
roid dysfunction, hyperprolactinemia, type 2 diabetes mellitus or
concomitant cardiovascular, renal, and liver dysfunctions. Other
causes of hyperandrogenism, such as Cushing syndrome/disease
and congenital adrenal hyperplasia, were excluded, after noc-
turnal fasting, by basal and/or stimulated (0.25 mg Synacthen®
iv, Biofutura Pharma S.p.A., Pomezia, Rome) plasma 17-OH-
progesterone levels. At the beginning of the study, the insulin resis-
tance and hyperinsulinism were, respectively, evaluated by using
the homeostatic model assessment (HOMA-ir) [(fasting glucose
(mmol/L)× fasting insulin (mIU/L)/22.5; n.v.<1.9 in our control
group of at least 200 normal healthy subjects (data not shown)]
and the 3-h oral glucose tolerance test (OGTT; 75 g of glucose)
for plasma glucose, insulin, and C-peptide levels. Whole-body
insulin sensitivity was calculated by using the insulin sensitivity
index derived from the OGTT (ISICOMPOSITE n.v. >6.0) accord-
ing to Matsuda and DeFronzo (21) considering normo-sensitive
subjects with values higher than 6.0 and low-sensitive those with
values lower than 4.0, respectively.
All women were studied in the follicular phase (days 1–7) of
the cycle, or after 2 or more months of amenorrhea, after a neg-
ative pregnancy test. After this diagnostic pathway, but before
of any pharmacological treatment, at each subject was admin-
istered the Millon Clinical Multiaxial Inventory-III (MCMI-III)
(22). The MCMI-III has been adapted to the Italian popula-
tion by a research group, which has involves the Universities of
Milan-Bicocca, Rome-La Sapienza, and Padua, coordinated by
Prof. Alessandro Zennaro, University of Turin, Italy (23, 24). We
used Millon words to explain personality disorder and clinical
syndrome.
In a subsequent day, for the first time in subject affected by
PCOS, Rorschach, which is considered a scientific, valid, and reli-
able projective test to assess personality, was administered accord-
ing to the Exner’s comprehensive system (CS), once adapted to
Italian population (24). The protocol was approved by the Local
Ethics Committee of both Padua and Bologna Hospital, and all
women gave their informed consent approval to collaborate with
this research. Eleven women invalidated the Rorschach protocols
because they have not given a sufficient number of answers in the
first tables, so the original group of the patients was reduced to
49 patients. All subjects aged from 19 to a maximum of 39 years
(25.80± 4.27 years), with comparable social and school degree
(from 13 to 18 years of school). Forty five women, with age (from
19 to 41 years; 25.2± 6.0), social, and school degree comparable,
were selected from a total of 2.500 records present in our data-
base, and considered as control group. Each control subject had a
normal menstrual cycle, was not hirsute, not taking any drugs or
abusing alcohol, did not smoke, and was matched to the subjects
with PCOS for body weight and age. Anonymity was assured to
each patient and names were substituted by an alphanumerical
progression.
TESTS AND SELECTION OF VARIABLES
The tests chosen for the personality analysis of the sample were (a)
the Rorschach Test administered, scored, and interpreted accord-
ing to the Exner’s CS (23, 24); and (b) The MCMI-III (22) is
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composed by 175 true/false items with 28 scales of which 14 refer
to personality disorders and 10 refer to clinical syndromes and the
remaining 4 refer to test validity indices. In MCMI-III scoring sys-
tem vary from 1 to 115 with a median score of 60 base rate (BR),
scores of 85 or above evidence a personality disorder, according to
DSM-IV axis II classification and/or the prominence of a clinical
syndrome, according to DSM-IV axis I diagnosis (24, 25). Ital-
ian version of MCMI-III shows good internal validity (Cronbach’s
alpha range for subscales= 0.66–0.90) and test-retest reliability
(r = 0.84–0.96) (23). The Rorschach tables were administered,
scored, and interpreted according to the Exner’s CS (24, 26, 27). It
was decided to select, besides the 27 variables proposed by Exner
and Andronikof-Sanglade (28) and by Bihlar and Carlsson (29),
further variables that we consider useful FD, SumT, SumC′, SumV,
SumY, Sum Shading, Sum Color Shading Blends, Sum Shading
Shading Blends, Wsum6, and An+Xy. Taking a cue from the work
of Sultan et al. (30), conducted on patients with mellitus diabetes
(IDDM), we wished to also consider part of their proposed indices.
LABORATORY AND PLASMA ASSAYS
Glucose was measured by using the glucose oxidase method
(Gluco-Quant®; Roche Diagnostics GmbH, Mannheim Ger-
many), its detection limit was 0.11 mmol/L. Insulin by means
of the two-site chemiluminescent immunometric immunoassay
(Immulite 2000; Diagnostic Products Corporation, Los Ange-
les, CA, USA) and its analytic sensibility was 2.0µIU/mL. The
intra- and inter-assay coefficients of variation (CVs) were <5.5
and 7.3%, respectively. LH, FSH, and E2 were measured by a
competitive immunoassay with the use of an electrochemilu-
minescence immunoassay (ECLIA; Roche Diagnostics GmbH,
Mannheim, Germany). Analytic sensibility of LH and FSH was
0.2 and 0.34 UI/L, respectively, whereas for E2 was 0.05 pmol/L.
The intra- and inter-assay CVs were 1.8 and 5.2% for LH, 2.0
and 5.3% for FSH, 5.7 and 6.2% for E2, respectively. Testosterone,
DHEA-s, 17-OHP, and A, after celite column chromatographic
separation, were assayed as previously described (31). Serum T
and DHEA-s were further measured by competitive immuno-
metric chemiluminescent enzyme immunoassay (Immulite 2000;
Diagnostic Products Corporation, Los Angeles, CA, USA). The
detection limit was 0.35 nmol/L for T and 0.08µmol/L for DHEA-
s, respectively, the inter- and intra-assay CVs were below 7.4%
for T and below 6% for DHEA-s. A and OHP were measured
by using an enzyme-linked immunosorbent assay, ELISA (DRG
Instruments GmbH, Marburg, Germany) and their detection limit
was 0.6 nmol/L for A and 0.18 nmol/L for OHP, respectively, with
intra- and inter-assay CVs <9.1 and 12.1% for A and 7.8 and
9.4% for OHP, respectively. SHBG was measured by using two-site
chemiluminescent immunometric assay (Immulite 2000; Diag-
nostic Products Corporation, Los Angeles, CA, USA), its analytic
sensibility was 0.8 nmol/L with intra- and inter-assay CVs <5.3
and 6.6%, respectively.
ANALYSIS OF THE DATA
The anthropometric and hormonal data were reported as
mean± SD. All continuous variables were compared using the
Student’s t -test for unpaired data. Glycometabolic and hormonal
data from PCOS and control groups were compared and ana-
lyzed with repeated measures by ANOVA. Mann–Whitney U test
and Wilcoxon paired rank test were also used for evaluating the
distribution of non-parametric values. Values for p< 0.05 were
considered significantly different.
For an in-depth approach to the psychological investigation
of our samples, we carried out the following analyses – com-
parison of the BR points obtained from the administration of
MCMI-III under the original norms proposed by Millon et al. (22);
statistical comparison of the average values of the Rorschach vari-
ables selected with the most recent norms proposed by Exner and
Erldberg (26) through the use of confidence intervals (CI 95%);
statistical percentage comparison of the threshold values of the
same variables with those proposed by Exner (25), ambitent sub-
ject, non-patient norms. The reference to the descriptive statistics
of the ambitent subjects is justified by the confirmation that, on
average, this coping style is representative of the M: WSumC rela-
tionship present in the PCOS sample (M = 2.25: SumC= 4.133).
Comparison of Rorschach Indices [suicide constellation (S-Con),
coping deficit index (CDI), depression index (DEP-I), perceptual-
thinking index (PTI), schizophrenia index (SCZI), hypervigilance
index (HVI)] obtained from subjects with PCOS were done with
those obtained from control group recorded in our database.
RESULTS AND DISCUSSION
Auxological and endocrine–metabolic parameters of our sub-
jects are summarized in Table 1. As expected, hyperandrogenic
parameters were elevated in women affected by PCOS and signifi-
cantly different when compared with Control group. In particular,
LH/FSH ratio and serum androgens, above all testosterone, were
significantly higher in PCOS than in Controls. Also, metabolic
parameters and insulin resistance were significantly elevated in
patients with PCOS, whereas, as expected by the enrollment cri-
teria, body weight (calculated as BMI) did not differ between the
groups.
When we analyzed personality disorders scales, by MCMI-III,
in PCOS group, we observed that several diseases, diagnosed in
according to DSM-IV axis II, reached percentage significantly
higher than in controls. In Figure 1, in fact, we summarized the
Table 1 | Characteristics of women with PCOS and healthy controls.
PCOS (n=49) Control (n=45) p
AGE (years) 25.8±4.7 25.2±5.9 n.s
BMI (kg/m2) 27.6±4.8 24.9±4.4 n.s
Waist (cm) 78.2±6.8 69.5±3.7 <0.05
PRL (µg/L) 23.0±8.6 11.9±5.3 <0.05
LH/FSH (ratio) 2.80±0.4 1.09±0.2 <0.02
DHEA-S (µmol/L) 7.01±2.5 5.50±3.34 n.s
17-OH-P (nmol/L) 2.68±0.46 1.46±0.38 <0.05
A (nmol/L) 12.7±1.2 6.08±0.71 <0.02
T (nmol/L) 2.96±0.2 0.85±0.3 <0.005
E2 (pmol/L) 123±26 104±34 n.s.
SHBG (nmol/L) 24.6±7.9 54.7±13.6 <0.03
FAI (free androgen index) 12.0±1.33 1.55±0.6 <0.005
HOMA-ir 2.46±0.42 1.45±0.36 <0.05
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FIGURE 1 |The incidence of traits and of personality disorders
(DSM-IV axis II) recorded through MCMI-III in personality scales
(BR≥75 is personality trait; BR≥85 is disorder) (22). Legend: Sc,
schizoid; A, avoidant; Dp, depressive; De, dependent; H, histrionic;
N, narcissistic; An, antisocial; S, sadistic; C, compulsive; Ne,
negativistic; M, masochistic; Sy, schizotypal; B, borderline;
P, paranoid; ap<0.05 vs. Cont; bp<0.01vs. Cont; cp<0.005
vs. Cont.
most important personality disorders in PCOS group compared
with those observed in the control group. However, whether this
increased incidence of personality disorders in patients affected by
PCOS can be considered a link with clinical signs of hyperandro-
genism remain at present unclear. In fact, the majority of studies
showed a linkage between psychological disorders and major clin-
ical PCOS symptoms, such as excessive body hairs, acne, infertility,
or excessive body weight (4–6, 10, 13, 32, 33). Our results, in con-
trast, indicated that an intrinsic psychopathological characteristic
of PCOS can be really consistent. According to our hypothesis,
there are only three articles (17, 18, 34) that evidenced personality
disorders in patients affected by PCOS, diagnosed by Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV). However,
these latter studies recorded lower percentage of psychological
disorders, when compared with our data, so suggesting that a het-
erogeneous expression of the same psychopathological diseases
can exist in PCOS or it was assessed a heterogeneous pool of sub-
jects affected by PCOS, therefore, further studies that consider the
same Diagnostic Criteria for PCOS and a more numerous group
of person are needed. When we considered the results of clinical
syndrome scales, diagnosed according to DSM-IV axis I Crite-
ria, we also found several clinical psychopathological disorders,
as summarized in Figure 2. The most representative disorders
were anxiety (about 10.0%) and depression (about 16.0%). These
analyses, in fact, seem to confirm recent data obtained in PCOS
patients (17), which showed a frequent finding of psychiatric dis-
orders. Interesting to note that in our sample we didn’t observe
neither alcohol addiction nor drug addiction or post-traumatic
stress disorders. Because, we also observed different incidences
(from 30.0% to about 70%) of psychopathological diseases, such
as anxiety, mood, or thought disorders, using different psychome-
tric test, it can be also suggested that different clinical expressions
of psychopathological diseases can exist in PCOS. Also, other
data, analyzed by different questionnaires, confirmed a prevalent
expression of anxiety and depression, further suggesting that an
elevated rate of mental illness in these hyperandrogenic patients
(11, 14, 35). Again, Klipstein et al. (36) evidenced a rate of about
30.0% of bipolar disorder types I and II and Rassi (37) of about
Frontiers in Endocrinology | Neuroendocrine Science November 2014 | Volume 5 | Article 185 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scaruffi et al. Personality disorders in PCOS
FIGURE 2 |The incidence of clinical disorders scales (DSM-IV axis I)
(BR>75) and of full blown clinical syndromes (BR>85) recorded
through MCMI-III (22). Legend: anxiety; Somat, somatoform; bipolar;
Dysthy, dysthymia; Tho Dis, thought disorder; Major Dep, major depression;
Delu Dis, delusional disorder.
11.0% of patients, respectively. Our data are in agreement with
these latter results, so further evidencing that women with PCOS
had a rate of mental illness several times higher (three to five-
fold), when compared with normal population. However, the
absence of rigorous diagnostic criteria of PCOS can not exclude
an enrollment of heterogeneous groups of patients, so reducing
the diagnostic capacity and, of consequent, the percentage of psy-
chopathological diseases in the PCOS per se. Results of Rorschach
test, obtained from our patients, are summarized in Table 2 and
Figure 3. We used as control a group of 45 healthy Italian subjects
already recorded in our database and gently provided by Zennaro
(23). We used this trick because in Italy, at present, there are no
any data about this pathology.
Using a statistical comparison (Student’s t -test for independent
groups) between the samples of patients and the control group, we
have evidenced significant differences among several variables, as
showed in Table 2. Calculating Cohen’s d, the effect size (statis-
tically significant >0.6) underlined a high effect for 10 of these
variables: WSum6, AdjD, ego impairment index (EII), MOR, Pop-
ular, Shading Blends, SumT, SumV, Sum Shading e Sum6. Our
data show an important deficit in cognitive functions (MEDIA-
TION and IDEATION clusters). Cohen’s d underlines as “high
effects” (≥0.6) of the following variables: X+%, WSum6, AdjD,
COP, GHR, Popular, SumV, SumY, Sum Shading, and Sum6. The
following variables, WSum6, SumV, Sum Shading, Sum6, are sig-
nificantly higher. The variables, X+%, COP, GHR, Popular, were
significantly lower, while AdjD was actually negative. All these data
evidenced that in subjects with PCOS exists a massive reality dis-
tortion (XA%, X−%, X+%, EII, PTI index, and SCZI index)
with incoherent and disorganized thoughts (Sum6 and Wsum6),
failures in the ability to judge, bizarre, or magical ideations and
with interpersonal communication difficulties. PTI was positive
for 30.6% of patients as well as SCZI for 20.4% of our sam-
ple, therefore, we can underline as “daily life” is really difficult
for the majority of our patients affected by PCOS, because mis-
perception leads to behavior often inappropriate in social life.
Again, a large proportion (63.3%) of patients (X−%> 0.25)
were displayed serious perceptual inaccuracies, stressing therefore
how the reality was not adequately perceived because emotions
distorted it (X−%, X+%). Again, 42.9% of subjects (Xu%= 0.2)
were anti-conformism, displaying a tendency to originality, but
53.1% (Populars≤ 4) rejected conventional models, so adopt-
ing behaviors not socially adequate and/or accepted. Ninety-two
percent of subjects with PCOS (X+% <0.70) showed a percep-
tion of the situations and words in an unusual manner. About
four (4.1) % (Populars≥ 8) of our sample was exaggerated in
conformism. These latter patients usually need a positive social
judgment and they need the approval of other people. In our
sample, 26.5% (lambda< 0.30) had an inadequate control over
emotions that interfere with logical functions. EII showed seri-
ous impairment in 38.8% of the sample, moderate in 18.4%,
average in 8.2%, and slight in 24.5% (X−%, Sum6, WSum6
and EII higher, XA%, WDA%, X+% lower). Only 10.0% of
women analyzed, had a normal, non-pathological values. Accord-
ing all these results, we evidenced that our patients had really
difficulties in organizing the stimulus when they face the real-
ity, so forcing them to use more psychic energy than needed
(WDA<XA%). However, in our study about 12.2% of patients
(12 subjects) ignored the complexity of the reality and tended to
simplistic situations and interpersonal relationships. Again, 40.8%
were very self-involved (Egoindex≥ 0.45) and about 30% built
up their own self-esteem, by considering themselves better than
others (Fr+Rf= 1). This focus on self could be detrimental in
the interpersonal relationship and could contribute to reality dis-
tortion. Our data seem to confirm Willmott’s results (38) that
evidenced as women with PCOS exhibit a lack of control over
their own lives’ events. Considering the CDI, we found it posi-
tive for 53.1% of the patients (vs. 29% of the controls), revealing
a deficit in coping abilities, and consequently interpersonal rela-
tionships were superficial and rarely maintained. Also, social skills
appeared to be reduced (CDI, EA) and interpersonal relationships
were perceived as unsatisfying. About thirty (30.6) % of PCOS
sample had a damaged and negative interpersonal relationship
representation (PHR higher). Interactions of personal situations
were perceived as not cooperative, but in a hostile manner. All of
this creates, in our patients, a state of chronic stress, which was
reflected in a cognitive slippage. More than 50% of our patients
resulted depressed (DEP-I positive) and with a percentage signifi-
cantly higher than observed in controls (55.1 vs. 25.0% controls).
Unexpectedly, 8.1% of patients with PCOS (vs. 6% of the con-
trols) were at risk for suicide (S-Con positive, MOR= 2, FD> 2,
Shadings). These latter results were in agreement with previous
studies that underlined how this psychopathological tendency was
more frequently observed in women with PCOS (35). However,
at present, whether suicide can be cause or effect of high level
of discomfort induced by clinical or psychological signs, or both,
remains still unknown. In expected manner, several authors (39,
40) reported a high prevalence of negative self image and poor
body image in subjects with PCOS. Also, in our PCOS group,
with respect of controls, we evidenced a significant higher, about
18.0%, a self image damaged (MOR= 2). Again, about 45% of
patients had an exaggerated introspective behavior (FD≥ 2) that
it could became a pathological self criticism and a ruminative
thinking. This point of view is important, because women with
PCOS had a negative and pessimistic view of themselves; therefore,
they had constant need of reassurance about their own value
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Table 2 | Comparison between PCOS and control groups using t -test for independent samples.
Rorschach variables PCOS group (n=49) Control group (n=45) T p Cohen’s d
Mean±SD Mean±SD
Age 25.80±4.27 24.80±6.77
R 21.59±6.68 23.35±8.170
Lambda 0.606±0.5576 0.5728±0.4800
FQM− 0.88±1.3 1.18±1.279
FQS− 1.12±1.39 1.63±1.628
FD 0.92±0.91 1.35±1.562
XA% 69.94±12.27 71.35±12.949
WDA% 75.06±12.62 73.45±11.964
X+% 42.45±13.24 47.58±13.769 −1.777 0.079 −0.37
Xu% 27.45±1.49 23.78±9.983
X−% 28.49±11.99 27.78±3.318
S−% 16.57±21.51 22.98±22.273
WSum6 23.55±13.27 11.43±10.77 4.759 0.000 1.003
WSumC 4.133±2.345 3.338±2.092
EA 6.684±3.556 7.888±3.888
ES 12.22±6.28 11.68±5.25
D −1.73±2.09 −1.15±1.46
AdjD −0.96±1.65 −0.30±1.159 −2.212 0.030 −0.464
Afr 0.445±0.1605 0.488±0.1281
EGO index 0.42±0.1685 0.4432±0.1792
EII 1.213±1.0866 0.489±1.1050 3.099 0.003 0.66
AG 0.20±0.50 0.45±0.815
MOR 0.86±1.17 2.05±1.867 −3.515 0.001 −0.763
COP 0.51±0.94 0.98±1.121 −2.092 0.040 −0.454
GHR 2.12±1.55 3.98±1.790 −5.156 0.000 −1.110
PHR 3.47±2.61 3.70±2.44
POP 4.20±2.09 5.63±1.917 −3.338 0.001 −0.712
Blends 5.67±0.44 5.58±3.727
Color Sh. blends 1.41±1.31 1.00±1.320
Shading Sh. blends 1.06±1.34 0.33±0.829 3.166 0.002 0.653
SumC′ 3.08±2.26 2.53±1.894
SumT 1.43±1.34 0.75±0.776 2.986 0.004 0.621
SumV 1.65±1.70 0.70±0.966 3.319 0.001 0.686
SumY 2.53±1.95 1.88±2.174
Sum shading 8.69±4.85 5.85±4.123 2.990 0.004 0.631
Fr+Rf 0.71±0.87 0.83±1.130
IsoIndex 0.226±0.1222 21.28±12.649
Sum6 7.02±3.53 3.68±2.99 4.842 0.000 1.021
Intell 2.59±2.04 2.85±2.842
An+Xy 1.96±0.3 0.90±1.215 2.783 0.007 0.576
Schizo index 2.88±1.48 2.68±1.70
PTI 1.80±1.41 1.63±1.59
HVI 2–8 2.29±1.53 3.23±2.057 −2.398 0.019 −0.518
DEP-I 4.73±1.22 4.25±1.214 1.869 0.065 0.394
CDI 3.33±1.3 2.90±1.128
S-Con 5.88±1.18 5.40±1.736
and had serious problems of establishing intimate relationship
(18.4% Fr+Rf≥ 2). In our patients, we recorded about 25% of
the samples (vs. 7% of healthy and normal subjects) constantly
in alert (HVI) and consequently worried, therefore, this mood
justifies how the majority part of the subjects examined, about
64% of PCOS, lived with a constant state of anxiety (SumY≥ 2).
It was interesting to underline that similar results were obtained
both in depressed patients and in subjects with juvenile diabetes
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FIGURE 3 |The percentage in the sample of positive results to
Rorschach indices (S-Con≥8, CDI≥4, DEP-I≥5, PTI≥3, SCZI≥4,
HVI≥4 ifT =0). Legend: S-Con, suicide constellation; CDI, copy deficit
index; DEP-I, depression index; PTI, perceptual-thinking index; SCZI,
schizophrenia index; HVI, hypervigilance index; ap<0.05; bp< 0.01;
cp<0.002.
mellitus type I (30). And again, it was suggested that the obser-
vation of Monzani et al. (41) who emphasized how in subjects
affected by PCOS scores of somatization, anxiety, and depres-
sion variables reached higher values when compared with normal
people. At the same time, these authors interestingly did not
observe any relevant psychopathological disorders, but differently
noticed that the subjects tend to hidden and/or clear behaviors
typical of the opposite gender. Moreover, the same women tended
to conform themselves to social standards, so probably reduc-
ing the perception of their “diversity.” Our data, therefore, seem
to confirm these results that report how ill women have altered
body self-perception, sexual intimacy, sexual dissatisfaction, and
the strong opinion that their partners’ sex life is as unsatisfac-
tory as their own, so indicating that PCOS is perceived as a real
disease (42).
About 60% of PCOS women experienced painful emotions and
high sense of insecurity, confusion, and ambivalence in relation
to emotions (Color Shading Blends> 1 in 69.4% and Shading
Blends> 1 in 61.2%), showed a low self-esteem (36.7% with
Egoindex< 0.32), and feel anxious, tense, nervous, and irritable
(more than 71.0% showed FQS-higher). All these data evidenced
that these women did not tolerate frustration and they were impul-
sive (D< 0). About 70.0% was feared to affective stimuli and avoid
them (Afr lower) and experienced discomfort with introspection,
because feelings of inferiority and depressed feelings (SumV≥ 1).
We observed that many of the samples (69.4%) did not use intellec-
tualization (Intell> 3) as a defense mechanism against affects, but
tended to avoid (Afr) situations where they were generated. Since
several patients affected by PCOS tended to isolate themselves,
to refuse interpersonal relationships, to present social phobia, or
tended to be worried and keep at a certain emotional distance
from others, it can be concluded that these subject are not very
interested in interpersonal relationship. However, our results, in
different manner, evidenced that about 60% of patients tended to
actively research contact and interpersonal relationships (Isoin-
dex< 0.25). Because, we studied a group of young patients, with
the majority of them in a period of university study, where the
interpersonal contacts are very high, we cannot exclude that we
have enrolled a group of patients with different social or cultural
impact.
CONCLUSION
Our results clearly highlight that in our patients, affected by PCOS,
exist mood and severe thought disorders with perceptual distor-
tion in about half of subjects. In this hyperandrogenic syndrome,
women have elevated dysphoric feelings, chronic emotional stress,
and several difficulties in social skills and daily life. In our group
of patients, to attenuate an important painful emotional overload,
many avoid interpersonal relationships and emotional inputs.
Again, intimate relationships can often cause fear and frustration.
All these conditions suggest that the characteristics of psycholog-
ical suffering in PCOS can constitute a distinguishing element,
which, for some aspects, appears to be so represented and shared
by the sample as to be promoted to a proper diagnostic indicator.
We also underline that the knowledge of these psychopatho-
logic aspects may ameliorate the doctor–patient interaction and
relationship with a desirable improvement on the medical exam-
ination, sensibility, and probably reaching greater adherence to
diagnostic and medical therapy.
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